Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (l19) to the ED-B domain of fibronectin

International Journal of Cancer

Volumn 102, Issue 1, 2002, Pages 75-85

  Borsi, Laura ^a   Balza, Enrica ^a   Bestagno, Marco ^b   Castellani, Patrizia ^a   Carnemolla, Barbara ^a   Biro, Attila ^c   Leprini, Alessandra ^c   Sepulveda, Jorge ^b   Burrone, Oscar ^b   Neri, Dario ^d   Zardi, Luciano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c Philogen SpA   (Italy)

^d ETH ZURICH   (Switzerland)

Author keywords

Antibody formats; Cancer diagnosis and therapy; Clinical applications; Tumor targeting; Tumor vasculature

Indexed keywords

ANTIBODY L19; FIBRONECTIN; IMMUNOGLOBULIN G1; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RADIOIODINATION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODY FORMATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRONECTINS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN FRAGMENTS; IODINE RADIOISOTOPES; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; PROTEIN ISOFORMS; RADIOPHARMACEUTICALS; TERATOCARCINOMA; TISSUE DISTRIBUTION;

EID: 0036837633     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10662     Document Type: Article

References (52)

1. Shawler DL, Bartholomew RM, Smith LM, Dillman RO.Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985;135:1530-5.
2. Miller RA, Oseroff AR, Stratte PT, Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983;62:988-95.
3. Hakimi J, Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991;147:1352-9.
4. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-74.
5. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7.
6. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990;50:1495-502.
7. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-4.
8. Lowman HB, Bass SH, Simpson N, Wells JA. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry 1991; 30:10832-8.
9. Nilsonn F, Tarli L, Viti F, Neri D. The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 2000; 43:165-96.
10. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Ann Rev Immunol 1994;12: 433-55.
11. Reichert JM. Monoclonals antibodies in the clinic. Nature Biotech 2001;19:819-22.
12. Huls GA, Heijnen IAFM, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der Vuurst de Vries A-R, Loyson SAJ, Helfrich W, van Berge Henegouwen GP, van Meijer M, de Kruif J, Logtenberg T. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nature Biotech 1999;17:276-81.
13. Pini A, Viti F, Santucci A. Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76.
14. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improve selective tumor delivery of single-chain Fv antibodies, Cancer Res 1998;58:485-90.
15. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59:347-53.
16. Neri D, Zardi L. Affinity reagents against tumour-associated extracellular molecules and newforming vessels. Adv Drug Deliv Rev 1998;31:43-52.
17. Bissel MJ, Radisky D. Putting tumours in context. Nature Rev Cancer. 2001;1:46-54.
18. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
19. Balza E, Borsi L, Allemanni G, Zardi L. Transforming growth factor β regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett 1988;228:42-4.
20. Carnemolla B,Balza E,Siri A,Zardi L,Nicotra MR, Bigotti A, Natai PG. A tumor- associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139-48.
21. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L. Transforming growth factor-β regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990;261:175-8.
22. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995;270:6243-5.
23. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-42.
24. ffrench-Constant C, Van De Water L, Dvorak HF, Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 1989;109:903-14.
25. Castellani P, Viale G, Dorcaratto A, Nicol̀ G, Kaczmarek J, Querzé, G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-8.
26. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999;94:192-8.
27. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996;68:397-405.
28. Neri D, Carnemolla B, Nissim A, Leprini A, Querzè, G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform, Nature Biotech 1997;15:1271-5.
29. Demartis S, Tarli L, Borsi L, Zardi L, Ned D. In vivo targeting of tumour neo-vasculature by a radiohalogenated human antibody frament specific for the ED-B domain of Fibronectin. Eur J Nucl Med 2001;28:4534-9.
30. Birchler MB, Viti F, Zardi L, Spiess B, Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nature Biotech 1999;17:984-8.
31. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infraction of solid tumors in mice. Cancer Res 2001;61: 711-6.
32. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L. Enhancement of the antitumor properties of interleukin interieukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99:1659-65.
33. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D. Enhancement of the anti-tumor activity of interleukin-12 by targeted delivery to neo-vasculature. Nature Biotech 2002;20:264-9.
34. Wu AM, Yazaki PJ, Tsai S-W, Nguyen K, Anderson A-L, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JYC, Toyokuni T, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 2000; 97:8495-500.
35. Li E, Pedraza A, Bestagno M, Mancardi S, Sanchez R, Burrone O. Mammalian cell expression of dimeric small immune proteins (SIP). Protein Engineering 1997;10:731-6.
36. Pini A, Spreafico A, Botti R, Neri D, Neri P. Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma. J Immunol Meth 1997;206: 171-83.
37. Batista FD, Anand S, Presani G, Efremov DG, Burrone OR. The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors. J Exp Med 1996;184:2197-205.
38. Riske F, Hakimi J, Mallamaci M, Griffin M, Pilson R, Tobkes N, Lin P, Danho W, Kochan J, Chizzonite R. High affinity human IgE receptor (FceRI): analysis of the functional domains of the alpha-subunit with monoclonal antibodies. J Biol Chem 1991;266:11245-51.
39. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson J-P, Koch M, Monneret C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195-201.
40. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
41. Jain RK. Vascular and interstitial physiology of tumors. Role in cancer detection and treatment. In: Bicknell R, Lewis CE, Ferrara N, eds. Tumour angiogenesis. New York: Oxford University Press, 1997. 45-59.
42. Jain RK. Transport of molecules, particles, and cells in solid tumors. Ann Rev Biomed Eng 1999; 1: 241- 63.
43. Buchegger F, Haskell CM, Schreyer M, Scazziga BR, Randin S, Carrel S, Mach JP. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 1983;158:413-27.
44. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
45. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, Hu SZ, Odom-Maryon T, Wong JY, Shively JE. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996;2:21-36.
46. Wu AM, Williams LE, Zieran L, Padma A, Sherman M, Bebb GG, Odom-Maryon T, Wong JYC, Shively JE, Raubitschek AA. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 1999;4:1-12.
47. Hu S, Shively A, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE,. Wu AM. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56:3055-61.
48. Adams GP, McCartey JE, Tai MS, Oppermann H, Huston IS, Stafford WF 3rd, Bookman MA, Fand I, Houston LL, Weiner LM. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-34.
49. Turner H, Kinet JP. Signalling through the high-affinity IgE receptor FceRI. Nature 1999; 402(suppl):B24-B30.
50. Vangelista L, Laffer S, Turek R, Gronlund H, Sperr WR, Valent P, Pastore A, Valenta R. The immunoglobulin-like modules Cε3 and α2 are the minimal units necessary for human IgE-FcERI interaction. J Clin Invest 1999; 103: 1571-8.
51. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα. Nature 2000;406:259-66.
52. Magnani P, Fazio F, Grana C, Songini C, Frigerio L, Pecorelli S, Mangili G, Colombo N, Mariani CD, Paganelli G. Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy. Br J Cancer 2000;82:616-20.